Positive News SentimentPositive NewsNASDAQ:GLPG Galapagos (GLPG) Stock Price, News & Analysis $32.41 -0.50 (-1.52%) Closing price 04:00 PM EasternExtended Trading$32.41 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Galapagos Stock (NASDAQ:GLPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galapagos alerts:Sign Up Key Stats Today's Range$32.34▼$33.2550-Day Range$27.05▼$33.3952-Week Range$22.36▼$33.86Volume200,424 shsAverage Volume325,631 shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$25.33Consensus RatingStrong Sell Company Overview Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Read More Galapagos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreGLPG MarketRank™: Galapagos scored higher than 7% of companies evaluated by MarketBeat, and ranked 934th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingStrong Sell Consensus RatingGalapagos has received a consensus rating of Strong Sell. The company's average rating score is 1.38, and is based on no buy ratings, 3 hold ratings, and 5 sell ratings.Amount of Analyst CoverageGalapagos has only been the subject of 1 research reports in the past 90 days.Read more about Galapagos' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galapagos' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.76% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Galapagos has recently increased by 14.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.76% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Galapagos has recently increased by 14.91%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentGalapagos has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Galapagos this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Galapagos to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 32.46% of the stock of Galapagos is held by institutions.Read more about Galapagos' insider trading history. Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLPG Stock News HeadlinesGalapagos NV Launches New Subscription Right Plan for ManagementAugust 7, 2025 | tipranks.comGalapagos Creates New Subscription Right PlanAugust 7, 2025 | globenewswire.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.August 28 at 2:00 AM | SmartAsset (Ad)Galapagos shares drop 6% as Deutsche Bank cuts rating on strategy concernsAugust 7, 2025 | investing.comGalapagos NV Secures FDA RMAT Designation for GLPG5101August 6, 2025 | tipranks.comGalapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell LymphomaAugust 6, 2025 | globenewswire.comDeutsche Bank downgrades Galapagos to Sell amid ‘too much uncertainty’August 6, 2025 | msn.comGalapagos Appoints New Directors to Strengthen BoardJuly 23, 2025 | tipranks.comSee More Headlines GLPG Stock Analysis - Frequently Asked Questions How have GLPG shares performed this year? Galapagos' stock was trading at $27.50 on January 1st, 2025. Since then, GLPG shares have increased by 17.9% and is now trading at $32.41. How were Galapagos' earnings last quarter? Galapagos NV (NASDAQ:GLPG) issued its earnings results on Wednesday, April, 23rd. The biotechnology company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $2.24. The biotechnology company earned $97.33 million during the quarter, compared to analyst estimates of $72.22 million. Read the conference call transcript. When did Galapagos IPO? Galapagos (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are Galapagos' major shareholders? Top institutional investors of Galapagos include EcoR1 Capital LLC, Segall Bryant & Hamill LLC, Caption Management LLC and Primecap Management Co. CA. How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings4/23/2025Today8/28/2025Next Earnings (Estimated)10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLPG CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,310Year Founded1999Price Target and Rating Average Price Target for Galapagos$25.33 High Price Target$30.00 Low Price Target$22.00 Potential Upside/Downside-21.8%Consensus RatingStrong Sell Rating Score (0-4)1.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.08 Quick Ratio7.99 Sales & Book Value Annual Sales$275.61 million Price / Sales7.75 Cash Flow$0.74 per share Price / Cash Flow43.78 Book Value$47.57 per share Price / Book0.68Miscellaneous Outstanding Shares65,900,000Free FloatN/AMarket Cap$2.14 billion OptionableOptionable Beta0.10 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GLPG) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.